MarginsXMarginsX
Home › Markets › Health Care › IMRN

Immuron Limited (IMRN)

IMRN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.8996
+2.23% on the day
Market cap
$7.3M
Nano cap
Revenue · 2026
$5.2M
+2.5% on 2025
Net income · 2026
-$2.5M
-47.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1660046/000121390026102838/0001213900-26-102838-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2026-06-30. Converted from AUD at 1.4738 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerIMRN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryAustralia
IPO year2017
SEC CIK0001660046
SEC industry codePharmaceutical Preparations
Incorporated inAustralia

Financials · 2026

LineValue
Revenue$5.2M
Net income-$2.5M
Operating income-$2.6M
Net margin-47.7%
Operating margin-49.9%
Revenue growth+2.5%
Cash$6.1M
Total assets$8.9M
P/E (computed)Net income was not positive
P/S (computed)1.4×

Reported in AUD; shown in US dollars.

Warning signs

Cash runway
33.2 months
$6.1M cash at June 30, 2026
Share count, 1 year
+38.0%
2025-06-30 to 2026-06-30
Going-concern doubt
No
20-F filed September 24, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-09-24
Cash and burn$6.1M cash; operating cash flow -$553K a quarter.Report 2026-06-30
Shares outstanding8,071,202 (2026-06-30); 5,848,975 a year earlier.Cover page 2026-06-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-10-23
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrant Thornton Audit Pty Ltd, Melbourne, AustraliaPCAOB Form AP 2026-10-08
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2026
2026-06-30
$5.2M-$2.5M-$2.2M$6.1MNo debt tags$5.2M20-F 2026-09-24

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS SUPPLEMENT
424B52026-10-23
Latest annual report
ANNUAL REPORT
20-F2026-09-24
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-11-10

Source: SEC EDGAR submissions feed, 428 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+5.3%
1 month-15.9%
3 months-22.6%
Year to date+14.7%
1 year-43.9%
From 52-week high-52.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CURXCuranex Pharmaceuticals Inc$4.63-0.11%$7.3M
GTBPGT Biopharma Inc.$3.54-1.81%$7.3M
LGVNLongeveron Inc.$2.14-14.06%$7.2M
UPCUniverse Pharmaceuticals Inc.$1.48-1.99%$7.4M
XCURExicure Inc.$1.07-0.93%$7.0M
MBRXMoleculin Biotech Inc.$7.14-9.28%$7.6M
TPSTTempest Therapeutics Inc.$0.3418-10.50%$6.8M
SNGXSoligenix Inc.$0.2882-10.22%$6.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier